SUMMARY
The effects of four different doses of ursodeoxycholic acid (250, 500, 750, and 1000 mg daily) on biliary lipids were studied in 24 patients with radiolucent gallbladder stones. There was a significant increase in the proportion of ursodeoxycholic acid in bile after all doses, being greatest with 750 and 1000 mg daily. Unsulphated lithocholic acid was also increased in the bile after therapy, while the other major bile acids were reduced. The cholesterol content of bile was reduced by all doses, and this change was most marked after 1000 mg (from 109 ±1 4 to 5.6 ±0.5 mol %, P <0 01).
Biliary cholesterol saturation improved significantly only after 750 and 1000 mg daily.
Ursodeoxycholic acid (UDCA) is the 7 epimer of chenodeoxycholic acid (CDCA). Both agents are known to dissolve cholesterol gallstones. Whereas CDCA has been used in several large trials,'-6 experience with UDCA is less extensive and the two main studies have been in Japanese patients.7 8
Bile in cholesterol gallstone disease contains excess cholesterol, which cannot be held in stable solution by the bile acid-phospholipid micelles.9-14 Drugs which dissolve gallstones reduce the cholesterol content and saturation of bile and this reduction has been used to assess potentially useful agents.31-21 In addition, the extent of changes in bile has been used to estimate optimal dosage of CDCA.3 5 15 18 The data available at present on biliary lipid changes induced by UDCA therapy are either from small numbers of patients who have been treated with increasing doses'7 or from single fixed-dose regimens.2022 There have been no formal doseresponse studies to determine the differing efficacies of a range of doses of UDCA.
The present study was designed to compare the effects of four different doses of UDCA on bile chemistry in an attempt to define the minimal and optimal dosage for reducing the cholesterol content and saturation of bile to a level which might be expected to promote the dissolution of gallstones. 
Results
There was no difference between the groups of patients studied (Table 1) , who were similar for weight, height, and body build.
BILIARY LIPIDS
There was no significant difference between biliary lipids in group A and group B before UDCA administration ( Table 2 ). The molar percentage of cholesterol in bile was reduced 28% by 250 mg daily (P<0-05), 360o by 500 mg daily, 41o% by 750 mg daily (P<001), and 49% by 1000 mg daily (P<00l) ( Table 2 ). The change after 500 mg daily did not reach statistical significance because of two patients whose biliary cholesterol increased, in one from 9.4 to 17 2 mol00. Total bile acid content of bile was slightly increased after 1000 mg daily (P<0 05), but there was no change in phospholipids.
Neither 250 nor 500 mg daily produced a significant reduction in any of the indices of cholesterol saturation, though a trend to decrease was apparent (Table 2) . By contrast 750 mg daily produced significant and 1000 mg daily highly significant changes both in the saturation index and the uncorrected lithogenic index. The mean lithogenic index after 1000 mg daily (0.81 ±0 05) was significantly lower than the mean lithogenic index after 250 mg daily (1-07 ±0-12, P<0-05). However, when the lithogenic index was corrected for the UDCA content of bile, by subtraction from the calculated equilibrium cholesterol of the molar percentage biliary UDCAX 0037 as proposed by Carey and Ko,2f only 1000 mg daily produced a significant fall. Even then the mean value after treatment was not less than 1 (1-15+0-09).
There were striking increases in the UDCA content of bile after therapy, which were most marked (and similar) after 750 and 1000 mg daily ( There was a reduction in serum creatinine, which was significant at six months (from 89±6.0 to 77±4.6 ,tmol/l, P<0.02), and an increase in platelets which was also significant at six months (from Agents which are known to dissolve gallstones have the ability to produce a decreased cholesterol content and saturation in the bile. It has been suggested that the optimal dosage of CDCA can be inferred from the improvement in cholesterol saturation,3 51518 but we5 and others19 have been unable to confirm the reported correlation between achievement of bile unsaturation and gallstone dissolution in individuals.415 Therefore our findings that daily doses of 750 and 1000 mg UDCA produce a significant reduction in the indices of cholesterol saturation cannot be taken in themselves as indicating that these are optimal doses for gallstone dissolution for individuals. It will be necessary to relate the various doses to outcome of therapy as judged by gallstone disappearance and this study is at present under way.
The different bile acids have different abilities to solubilise cholesterol. In particular, UDCA has a markedly inferior capacity-to form bile acidcholesterol micelles compared with other bile acids in bile.26 28 29 Thus cholesterol saturation cannot easily be assessed accurately in bile which has been enriiched with UDCA. Some correction for the content of UDCA is necessary when calculating the lithogenic index. Ideally this is calculated for each individual bile sample with allowance for total lipid concentration. This is not feasible for duodenal aspirates which contain bile that has been diluted by varying degrees. A simple correction factor for the equilibrium concentration of cholesterol in a given bile acid-phospholipid solution has been proposed.26 28 From this a 'UDCA-corrected' lithogenic index can be calculated to give an approximation of the true ability of the bile to hold cholesterol in solution. Whether this newer concept will be more accurate in predicting gallstone dissolution and how closely will be shown to correlate with individual results has yet to be established.
Maton et al.'7 and Makino and Nakagawa,20 using 5 mg/kg/day and 150 or 600 mg daily, found significant falls in the uncorrected lithogenic indices at lower doses than we report. Although a trend to reduction can be distinguished on the lower doses on our study, it was only the larger doses which produced significant changes. We did not find any evidence that dose/unit body weight correlated better than absolute daily dose with cholesterol content and saturation of bile. The different patterns of bile acids in bile after UDCA and CDCA treatment make direct comparison of the effects of these agents difficult. However, the largest reduction in the molar proportion of cholesterol in bile that we encountered was after 750 and 1000 mg UDCA daily, which was similar to the changes which we have reported with 1000 mg of CDCA daily.5 Fedorowski et al.30 also found 1000 mg UDCA daily as effective as 1000 mg CDCA daily in a crossover study of predominantly non-gallstone patients to whom the bile acid was fed for two weeks; but Stiehl et al.22 found 750-1250 mg UDCA daily to be superior to similar doses of CDCA administered to gallstone patients over a three month period.
The progressive increase in biliary UDCA (Table  3) Any increase in biliary unsulphated lithocholic acid is potentially hepatotoxic.3233 Despite this theoretical hazard, there is a reassuring absence in humans of histological abnormality after UDCA therapy17 and serum lithocholic acid levels seem not to increase after UDCA therapy.22 UDCA does not produce the liver damage seen in Rhesus monkeys with CDCA.34 Abnormalities of those blood tests considered to reflect liver function were not seen in Japanese patients treated with UDCA8 20 but falls in yGTP, AST, and alkaline phosphatase have been observed in British patients." We observed no overall change in mean AST levels, and, while there was a reduction in yGTP concentrations, it did not reach statistical significance. Whereas we found that an alteration in bowel habit frequently required CDCA treatment to be adjusted,5 none of these 24 patients developed diarrhoea. This difference between the behaviour of dihydroxy bile acids could be because there is rapid conversion of UDCA to lithocholic acid, or possibly because UDCA does not induce the increased colonic water secretion and permeability known to be induced by CDCA. 35 UDCA is likely to exert its action by an effect within the enterohepatic circulation of bile acids because it is here that it is concentrated. It could act by increasing the total amount of bile acid in gallbladder bile relative to phospholipids and cholesterol, but this seems unlikely to be important in view of the absence of a decrease in the proportion of phospholipid and the fact that only a very slight increase in biliary bile acid was noted by us and by other groups.2022 A possible mode of action is via an alteration of cholesterol metabolism either from impaired intestinal absorption, or by reduced hepatic excretion after an increased conversion to bile acids, or by reduced synthesis either in the liver or the intestine. There is some evidence to suggest that hepatic cholesterol synthesis is reduced,17 and this could prove to be the mechanism for the improved cholesterol solubility in bile after UDCA administration.
The role of UDCA for the dissolution of radiolucent gallstones will need to be determined by assessment of its efficacy in long-term clinical studies. This bile acid has been reported to be at least as good as CDCA in Japanese patients2 7 8 and biliary lipid analysis shows that small doses of UDCA have a profound effect on biliary cholesterol. There are insufficient data to make a comparison possible in Caucasians either with CDCA or with the recently publicised agent Rowachol.38
At present, CDCA should be regarded as the agent of first choice for dissolution of gallstones because it has been extensively evaluated, but it is very costly. The manufacture of UDCA is also complex and it is even more expensive to produce. The only inexpensive agent which has been shown to dissolve gallstones is the relatively untried Rowachol.36 However, the acceptability and absence of overt toxicity of UDCA therapy make it an attractive alternative to CDCA for the dissolution of gallstones. 
